Scientists Discover an RNA Molecule That Shields the Brain From Alzheimer’s Damage

A long non-coding RNA with the unassuming name Loc646329 may be one of the brain’s quiet defenders against Alzheimer’s disease, according to a new study published in Molecular Biology Reports. Researchers in Iran report that this molecule, which does not code for proteins, appears to protect neurons from amyloid-beta toxicity by acting through a well-known signaling cascade called WNT/beta-catenin. When the team boosted Loc646329 in the hippocampus of Alzheimer’s model mice, the animals performed better in memory tests, carried fewer amyloid plaques, and showed stronger activation of a pathway that helps nerve cells survive.

Alzheimer’s disease is the most common cause of dementia, characterized by a slow, relentless loss of memory and cognition that accompanies the accumulation of amyloid-beta peptide in the brain, the death of neurons, and the formation of tangled proteins inside cells. Although decades of research have focused on amyloid itself, the upstream molecular switches that determine whether neurons resist or succumb to these insults remain only partly understood. The new work zeroes in on one such switch: a regulatory axis connecting a long non-coding RNA, a microRNA called miR-150, and the WNT/beta-catenin pathway, a signaling system long implicated in cell survival and brain maintenance.

Long non-coding RNAs, or lncRNAs, are transcripts longer than 200 nucleotides that are not translated into proteins. Once dismissed as transcriptional noise, they are now recognized as master regulators of gene expression, capable of sponging up microRNAs, guiding protein complexes to DNA, and modulating signaling pathways. In cancer research, lncRNAs that interact with the WNT/beta-catenin pathway have been extensively characterized, but their roles in neurodegeneration are far less explored. The team behind the new study set out to determine whether one particular lncRNA, Loc646329, might influence the course of Alzheimer’s disease.

The researchers began where many modern investigations do: with publicly available human sequencing data. By analyzing datasets of brain samples from Alzheimer’s patients and healthy controls, they examined how Loc646329 and miR-150 behave in the diseased brain. The datasets, including the publicly archived GSE63501 and GSE67333 series, provided the initial evidence that these two RNA molecules are implicated in the disease state, motivating the laboratory experiments that followed.

To test the mechanism directly, the team turned to SH-SY5Y cells, a human neuroblastoma cell line widely used to model neuronal biology. Fluorescence in situ hybridization revealed that Loc646329 resides predominantly in the cytoplasm, the cellular compartment where a lncRNA would need to be if it were to interact with microRNAs. Two complementary techniques then established the physical link: AGO2-RNA immunoprecipitation, which captures RNA molecules bound to the Argonaute 2 protein at the heart of the microRNA silencing machinery, and dual-luciferase reporter assays, which confirmed that miR-150 directly targets Loc646329. Together, these experiments painted a picture of Loc646329 as a competing endogenous RNA, or molecular sponge, that sequesters miR-150 and prevents it from dampening downstream targets.

The functional consequences of this interaction were tested under brutal conditions: the cells were exposed to aggregated amyloid-beta 1-42, the toxic peptide that accumulates in Alzheimer’s brains. When Loc646329 was overexpressed, the cells fared measurably better. A battery of assays told a consistent story. CCK-8 assays showed improved metabolic viability. EdU incorporation revealed that more cells retained proliferative capacity. Annexin V-FITC/PI flow cytometry and TUNEL staining, two independent measures of programmed cell death, both showed reduced apoptosis. In other words, raising the levels of this single non-coding RNA helped neurons withstand an otherwise lethal amyloid assault.

The mechanistic core of the study lies in what happens downstream of miR-150. The WNT/beta-catenin pathway is a major regulator of neuronal survival, and its dysfunction has been repeatedly linked to Alzheimer’s disease. A key player in this pathway is GSK3beta, an enzyme whose phosphorylation status determines whether beta-catenin, the pathway’s central messenger, is stabilized and allowed to travel to the nucleus to switch on survival genes, or is tagged for destruction. The researchers found that Loc646329 overexpression increased GSK3beta phosphorylation and stabilized beta-catenin, effectively turning up the volume on WNT signaling. Critically, when the team introduced synthetic miR-150 mimics into the cells, the protective effects of Loc646329 on these signaling events were blunted, indicating that the lncRNA’s benefits depend at least partly on its ability to neutralize miR-150.

Cell culture findings, however compelling, are only a prelude to the real test: does this matter in a living brain? To find out, the researchers used APP/PS1 mice, a transgenic strain that carries human amyloid precursor protein and presenilin mutations and progressively develops amyloid plaques and memory deficits resembling Alzheimer’s disease. Using stereotaxic injection, a surgical technique that allows precise delivery of material into defined brain regions, the team introduced an adeno-associated virus carrying the Loc646329 gene directly into the animals’ hippocampus, the brain structure essential for forming new memories.

The results were striking. In the Morris water maze, a standard behavioral test in which mice must learn the location of a hidden platform using spatial cues, the treated animals found the platform more efficiently than their untreated counterparts, demonstrating improved spatial learning and memory. Biochemical and histological analysis revealed the molecular underpinnings of this improvement: the treated mice had a reduced burden of amyloid-beta plaques and increased activation of beta-catenin in the injected brain region. The study thus connected the molecular sponge hypothesis to meaningful outcomes in an intact, diseased brain, a translation that many non-coding RNA studies never achieve.

The authors are careful to frame these findings as preclinical evidence rather than a therapeutic breakthrough. The work was conducted in cell lines and in a single mouse model, and the researchers themselves note that validation in primary neurons, human-derived neuronal models, and clinical samples is required before Loc646329’s therapeutic relevance can be established. delivering RNA-based therapies to the human brain remains a formidable challenge, and microRNA networks are notoriously context-dependent, with the same microRNA sometimes producing different effects in different cell types. Nevertheless, the study adds a compelling new name to the growing roster of non-coding RNAs implicated in Alzheimer’s disease, and it strengthens the case that the WNT/beta-catenin pathway is a druggable node worth pursuing. If subsequent studies confirm that boosting Loc646329 or blocking miR-150 can safely protect human neurons, the humble sponge molecule could one day inform entirely new strategies against a disease that currently has no cure.

Subject of Research: The role of the long non-coding RNA Loc646329 in regulating Alzheimer's disease-related pathology through the miR-150/WNT/beta-catenin signaling axis.

Article Title: LncRNA Loc646329 modulates Alzheimer’s disease-related phenotypes through the miR-150/WNT/β-catenin axis in cellular and APP/PS1 mouse models

Article References: Abdi, K., Amiri, M., Asadalizadeh, M., Khanmirzaei, A., Javanmard, A.-R., Rezaeimirghaed, O., Hajiesmaeili, M., & Ghaderian, S. M. H. (2026). LncRNA Loc646329 modulates Alzheimer’s disease-related phenotypes through the miR-150/WNT/β-catenin axis in cellular and APP/PS1 mouse models. Molecular Biology Reports, 53(1), Article 1594. https://doi.org/10.1007/s11033-026-12734-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12734-6

Keywords: Alzheimer's disease, lncRNA Loc646329, miR-150, WNT/beta-catenin signaling, neurodegeneration, amyloid-beta, neuronal apoptosis, APP/PS1 mice, non-coding RNA, hippocampus, gene regulation, GSK3beta phosphorylation